Good News from the EDQM, Strasbourg: Estriol capacity expansion at Hapila reaches another major milestone

We are delighted to announce another significant achievement in the Estriol capacity expansion project – a joint initiative between Hapila GmbH and Transo-Pharm Handels-GmbH.
 
The European Directorate for the Quality of Medicines & HealthCare (EDQM) has approved the extension of the Certificate of Suitability (CEP) for micronized Estriol. The CEP now covers not only our existing manufacturing facility (GMP Plant I), but also the newly commissioned GMP Plant III.
This approval significantly strengthens the robustness of our supply chain, effectively doubles our production capacity, and further enhances supply security for our partners worldwide.
 
By combining Hapila’s manufacturing and regulatory capabilities with Transo-Pharm’s commercial expertise, we continue to invest in a reliable, future-proof supply chain for Estriol and other high-quality pharmaceutical active ingredients.
Together, we are building a stronger, more resilient future for Estriol supply – driven by collaboration, quality, and long-term commitment.